Systemic fluconazole use linked to bleeding risk in atrial fibrillation patients: Study
Denmark: In a new study conducted by Anders Holt and team it was found that in patients with atrial fibrillation on apixaban, rivaroxaban, or dabigatran, a link was discovered between increased bleeding risk and the use of systemic fluconazole. The findings of this study were published in The American Journal of Medicine.
Despite clinical importance and multiple findings suggesting links, bleeding safety in connection to systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is understudied. In atrial fibrillation patients on apixaban, rivaroxaban, or dabigatran, this study looked at the risk of bleeding after either systemic antifungal treatment with fluconazole or topical antifungal treatment with any azole agent.
This study was based on administrative health registers from across Denmark that this group had previously used. Researchers identified individuals with atrial fibrillation who were started on apixaban, rivaroxaban, or dabigatran between 2012 and 2018 using Danish records. They then used a case-crossover design with 30-day exposure windows to look for links between bleeding occurrences and systemic fluconazole or topical azole medication and provided odds ratios (OR).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.